Life Science Mentors – Mentoring Service for Finnish Life Science Actors
Finnish industry organisations in the Life Science field have collaboratively created an internet based mentoring service for start-up companies, fledgling entrepreneurs and researchers interested in commercialising their inventions. The purpose of the service is to share the knowledge of experienced people with beginners and support their business development. The service is offered free of charge.
Faron Pharmaceuticals Admission to AIM and first day of dealings £10 million fundraise to progress Phase III clinical trial
Faron Pharmaceuticals Oy ("Faron”), the clinical stage biopharmaceutical company, is pleased to announce the commencement of dealings in its Ordinary Shares on the AIM market of the London Stock Exchange with effect from 8.00 a.m. today under the ticker FARN and the ISIN number FI4000153309. This follows a successful placing and subscription for 3,846,154 new Ordinary Shares, raising £10.0 million at a price of 260p per ordinary share (the “Fundraising”).
Faron Enters Agreement with Selexis SA to Progress Development of Novel Cancer Immunotherapy Clevegen
Faron Pharmaceuticals Oy (”Faron”), the clinical stage biopharmaceutical company, announced today it has entered into an agreement with Swiss-based Selexis SA. Under the agreement, Faron will have access to the Selexis SUREtechnology Platform™ and SURE CHO-M Cell Line™ for the production of high-expressing and stable clonal cell lines for use in the development and production of Clevegen, its novel cancer immunotherapy antibody.